Antiviral Nucleoside Inhibitors

Antiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases by mimicking host nucleosides, disrupting viral genome replication. They work by being incorporated into growing viral DNA strands, where they block further nucleotide addition and halt replication.

Acyclovir enters infected cells through passive diffusion. Once inside, virus-encoded thymidine kinase phosphorylates acyclovir to form acyclovir monophosphate. Host cellular kinases then sequentially convert it into its diphosphate and active triphosphate forms, which can then interfere with viral DNA synthesis.

Acyclovir lacks a 3'-hydroxyl group, which is essential for adding nucleotides to DNA chains. When acyclovir triphosphate is incorporated into viral DNA by viral DNA polymerase, this missing group prevents further nucleotide addition, prematurely terminating DNA synthesis and halting viral replication.

Acyclovir is a guanosine analog that selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), and varicella-zoster virus (VZV). Its preferential affinity for viral DNA polymerase over host polymerase enhances its selective toxicity against these herpesviruses.

Ganciclovir, another guanosine analog, targets cytomegalovirus (CMV). Zidovudine, a thymidine analog, is widely used for HIV treatment. Ribavirin is a broad-spectrum antiviral that disrupts replication of several RNA viruses through mechanisms including viral RNA polymerase inhibition and induction of lethal mutagenesis.

Combining multiple nucleoside inhibitors makes it more difficult for viruses to develop resistance, as they would need to simultaneously acquire multiple mutations to evade distinct mechanisms of action. This combination strategy is a cornerstone of antiviral therapy, particularly in managing chronic viral infections like HIV and hepatitis C.

Unlike inhibitors of bacterial protein synthesis or cell wall formation, acyclovir specifically targets viral DNA synthesis by mimicking a natural nucleoside. Its selective incorporation into viral DNA and chain termination mechanism exploits differences between viral and host polymerases, providing targeted antiviral activity without disrupting host cell function.